See inside every stock. Pro
S&P 5007,723▲ 0.60%Nasdaq26,478▲ 1.18%Dow Jones52,378▲ 0.03%Nasdaq 10029,651▲ 1.29%VIX17.52▼ 4.73%US Dollar102.35▲ 0.39%Gold spot4,006▲ 0.30%WTI101.16▲ 1.26%
KOSDAQ · Korea · Updated after 27 Oct 2026 close

Hugel Inc

145020 · KOSDAQ · prices in KRW
KRW 179,400.00▲ +3,000.00 (1.70%)
Research reportHistorical data

About Hugel Inc

Hugel Inc is a South Korean pharmaceutical company based in the city of Chuncheon. It develops and makes botulinum toxin products used for cosmetic wrinkle treatment and for therapeutic purposes, and it also produces hyaluronic acid dermal fillers. Its customers include clinics, hospitals and distributors in Korea and in overseas markets, where its aesthetic products are used by medical professionals. The company focuses on research, manufacturing and supply of these injectable treatments.

On this site Hugel Inc appears as a stock on the KOSDAQ (Korea), code 145020, with prices in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

58/ 100
Market X-Ray · price-based
Fair price profile
Ranks #648 of 1833 on the KOSDAQ · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Korea yet.
TrendFair
53/100
Mixed trend against its averages.
See the numbers →
Above 200-day average-26.5%
From 52-week high-39.5%
MomentumWeak
33/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-26.2%
6-month return-33.1%
12-month, skipping last month-28.6%
Stability (higher is calmer)Fair
69/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)57.6%
Worst drawdown, 1 year (smaller is calmer)-43.2%
LiquidityStrong
93/100
Trades actively.
See the numbers →
Avg daily value traded11,344.30M KRW
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Korea when fundamentals data for this market is added. All Korea stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
163,700.00 – 308,500.00
Price is 11% of the way up
Returns
−26.2% 3m · −31.5% 1y
Price returns, dividends not included
RSI (14)
39
Neutral zone

Price chart

52-wk range 163,700.00 – 308,500.00 Daily closes, split-adjusted

Signals

50-day average215,396.00
200-day average243,969.00
Golden/death cross (60d)Death, 33 days ago
New 52-week highNo
Bullish RSI divergenceYes
Average daily range (ATR)8,029.35

Technical summary

Daily
Strongly bearish
1 bullish · 4 neutral · 11 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10179,380.0Bullish
EMA 10180,426.4Bearish
SMA 20180,070.0Bearish
EMA 20186,125.0Bearish
SMA 50215,396.0Bearish
EMA 50206,261.0Bearish
SMA 100231,448.0Bearish
EMA 100223,687.8Bearish
SMA 200243,969.0Bearish
EMA 200240,314.5Bearish
Oscillators (daily)
RSI (14)38.83Neutral
MACD (12, 26)-9,563.3Bearish
Momentum (12)-1.86Bearish
Stochastic %K (14)59.47Neutral
Williams %R (14)-40.53Neutral
CCI (20)5.85Neutral
Pivot points (classic, last session)
S3
168,566.7
S2
172,933.3
S1
176,166.7
Pivot
180,533.3
R1
183,766.7
R2
188,133.3
R3
191,366.7
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in KRW. Educational only, not financial advice.